Form 4: CalciMedica Insider Reports Stock Option Activity

CalciMedica, Inc. reports on stock option transactions by Chief Scientific Officer Kenneth A. Stauderman.

Summary

• Kenneth A. Stauderman, Chief Scientific Officer of CalciMedica, Inc., reported a transaction involving employee stock options.
• The transaction involved 65,124 stock options with an exercise price of $0.585.
• These options are exercisable starting April 1, 2026, with vesting occurring in monthly installments over four years, contingent upon the filing of a Form S-8 registration statement.
• The shares underlying these options were automatically added to the company's 2023 Equity Incentive Plan on January 1, 2026, due to an annual 'evergreen' provision.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details standard stock option grants and vesting schedules rather than significant new financial performance or strategic shifts.

Positives

• The reporting person, Kenneth A. Stauderman, is actively involved with the company's equity incentive plan.
• The company has an 'evergreen' provision in its equity incentive plan, allowing for automatic addition of shares.
• The transaction date for the earliest transaction is April 5, 2026, indicating future-dated activity.

Negatives

• Vesting of the reported stock options is contingent on the filing of a Form S-8 registration statement, which has not yet occurred.
• The earliest transaction date is in the future (April 5, 2026), suggesting this is a planned or granted option rather than a completed sale or purchase.

Risks

• The vesting of 65,124 stock options is dependent on the company filing a Form S-8 registration statement, which introduces a regulatory risk.
• There is a risk that the Form S-8 filing may be delayed or not occur, impacting the vesting schedule of these options.

Future Outlook

The vesting of 65,124 stock options is scheduled to begin on April 1, 2026, with 1/48th vesting monthly over four years, contingent on the company filing a Form S-8 registration statement.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive compensation and potential insider confidence. The details of this option grant and its vesting conditions are typical for technology and biotech companies aiming to incentivize key scientific personnel.

Stakeholder Impact

• Shareholders: Gain insight into executive compensation structures and potential future dilution if options are exercised.
• Employees: The equity incentive plan structure may influence employee motivation and retention.
• Management: The filing confirms the ongoing compensation and incentive arrangements for key scientific leadership.

Next Steps

• The company must file a registration statement on Form S-8 covering the shares of Common Stock.
• Vesting of the reported stock options will commence upon the filing of the Form S-8 and continue monthly over four years.

Key Dates

Keywords

CalciMedica, CALC, Form 4, Stock Options, Insider Trading, Equity Incentive Plan, Securities Exchange Act, Beneficial Ownership, Kenneth Stauderman, Chief Scientific Officer